KCNQ2/3 (Kv7.2/7.3) potassium channel (opener)

Class

next-generation KCNQ2/3 potassium channel opener with improved ion-channel selectivity and metabolic/chemical stability versus first-generation openers (e.g., retigabine)

Pathway

opens KCNQ2/3 (M-current) potassium channels to reduce neuronal hyperexcitability underlying seizures

KCNQ2 and KCNQ3 (also called Kv7.2 and Kv7.3) are voltage-gated potassium channel subunits that assemble together in neurons to form the molecular basis of the M-current, a slow, non-inactivating potassium current that is active near the resting membrane potential. By allowing potassium ions to flow out of the neuron, this current opposes depolarization and limits repetitive firing, acting as a brake on neuronal excitability. Loss-of-function mutations in KCNQ2 or KCNQ3 reduce this braking effect and are associated with severe genetic epilepsies, while pharmacologically opening these channels can reproduce and extend that braking effect therapeutically. A KCNQ2/3 opener increases the probability that these channels are open at physiological voltages, hyperpolarizing neurons and raising the threshold needed to trigger or sustain abnormal, repetitive electrical activity such as seizures. This mechanism has broad relevance across epilepsy syndromes, including those driven by genetic KCNQ2/3 dysfunction, and has also been explored in pain and other conditions involving neuronal hyperexcitability. Later-generation openers in this class are designed to act more selectively on KCNQ2/3 relative to other ion channels, and to have more favorable chemical and metabolic properties, addressing limitations observed with earlier compounds in this category.